English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background  Metastatic epidermal growth factor receptor-mutated (EGFR + ) non-small-cell lung cancer (NSCLC) can present  de novo  or following previous nonmetastatic disease (secondary). Potential differences between these two patient subsets are unclear at present.    Methods  We retrospectively analyzed characteristics of tyrosine kinase inhibitor (TKI)-treated patients with  de novo  vs. secondary metastatic EGFR +  NSCLC until December 2019 (n = 401).    Results    De novo  metastatic disease was 4× more frequent than secondary (n = 83/401), but no significant differences were noted regarding age (median 66 vs. 70 years), sex (65% vs. 65% females), smoking history (67% vs. 62% never/light-smokers), and histology (both >95% adenocarcinoma). Patients with secondary metastatic disease showed a better ECOG performance status (PS 0–1 67%–32% vs. 46%–52%, p = 0.003), fewer metastatic sites (mean 1.3 vs. 2.0, p < 0.001), and less frequent brain involvement (16% vs. 28%, p = 0.022) at the time of stage IV diagnosis. Progression-free survival (PFS) under TKI (median 17 for secondary vs. 12 months for  de novo , p = 0.26) and overall survival (OS, 29 vs. 25 months, respectively, p = 0.47) were comparable.  EGFR  alterations (55% vs. 60% exon 19 deletions),  TP53  mutation rate at baseline (47% vs. 43%, n = 262), and T790M positivity at the time of TKI failure (51% vs. 56%, n = 193) were also similar. OS according to differing characteristics, e.g., presence or absence of brain metastases (19–20 or 30–31 months, respectively, p = 0.001), and ECOG PS 0 or 1 or 2 (32–34 or 20–23 or 5–7 months, respectively, p < 0.001), were almost identical for  de novo  and secondary metastatic disease.    Conclusions  Despite the survival advantage reported in the pre-TKI era for relapsed NSCLC, molecular features and outcome of TKI-treated metastatic EGFR +  tumors are currently independent of preceding nonmetastatic disease. This simplifies design of outcome studies and can assist prognostic considerations in everyday management of patients with secondary metastatic EGFR +  tumors.

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer